Tacrolimus in refractory polymyositis with interstitial lung disease.
| Publicado en: | Lancet Vol. 353; no. 9166; pp. 1762 - 1764 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Lancet
5/22/1999
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=1870552&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 1870552 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 5/22/1999 vid: 353 iid: 9166 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 1870552 1870552 NLM10347992 1870552 10.1016/S0140-6736(99)01927-3 NLM10347992 PMC2977932 1870552 ppf: 1762 ppct: 2 formats: fmt: @attributes: type: P tig: atl: Tacrolimus in refractory polymyositis with interstitial lung disease. aug: au: Oddis, Chester V. Sciurba, Frank C. Elmagd, Kareem Abu Starzl, Thomas E. Oddis, C V Sciurba, F C Elmagd, K A Starzl, T E sug: subj: Lung Diseases, Interstitial Drug Therapy Polymyositis Drug Therapy Tacrolimus Therapeutic Use Immunosuppressive Agents Therapeutic Use Lung Diseases, Interstitial Etiology Grip Strength Aged Human Tacrolimus Adverse Effects Immunosuppressive Agents Adverse Effects Polymyositis Complications Female Autoantibodies Blood Middle Age Polymyositis Immunology Adult Treatment Outcomes Creatine Kinase Blood Validation Studies Comparative Studies Evaluation Research Multicenter Studies Arthritis Impact Measurement Scales Scales Aged: 65+ years Middle Aged: 45-64 years Adult: 19-44 years Female pubtype: Academic Journal doctype: research Journal Article ougenre: Unknown ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|